Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection

Journal of Medical Virology

Volumn 85, Issue 11, 2013, Pages 1913-1918

  Durante Mangoni, Emanuele ^a,b   Vallefuoco, Luca ^c   Sorrentino, Rosanna ^c   Iossa, Domenico ^a   Perna, Enzo ^c   Molaro, Rosa ^a   Braschi, Umberto ^c   Zampino, Rosa ^a   Sodano, Giuseppe ^b   Adinolfi, Luigi Elio ^a,d   Utili, Riccardo ^a,b   Portella, Giuseppe ^c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b MONALDI HOSPITAL   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Internal Medicine   (Italy)

Author keywords

Antigens; Fatty liver; Hepatitis C; Viral

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B CORE ANTIGEN; INTERLEUKIN 28B; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CELL COUNT; CHEMOLUMINESCENCE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DNA POLYMORPHISM; FATTY LIVER; FEMALE; FERRITIN BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER CELL; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PROMOTER REGION; PROTEIN BLOOD LEVEL; QUANTITATIVE ASSAY; VIRUS GENE; WAIST CIRCUMFERENCE;

HEPATITIS C VIRUS;

ANTIGENS; FATTY LIVER; HEPATITIS C; VIRAL;

ADULT; AGED; ALANINE TRANSAMINASE; COHORT STUDIES; FATTY LIVER; GAMMA-GLUTAMYLTRANSFERASE; GENOTYPE; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HISTOCYTOCHEMISTRY; HUMANS; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL CORE PROTEINS; VIRAL LOAD;

EID: 84883052865     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23672     Document Type: Article

References (14)

1. Abe H, Hayes CN, Ochi H, Tsuge M, Miki D, Hiraga N, Imamura M, Takahashi S, Kubo M, Nakamura Y, Kamatani N, Chayama K. 2011. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 83:1597-1607.
2. Adinolfi LE, Durante Mangoni E, Zampino R, Ruggiero G. 2005. Hepatitis C virus-associated steatosis-pathogenic mechanisms and clinical implications. Aliment Pharmacol Ther 22:52-55.
3. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. 2001. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33:1358-1364.
4. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Bréchot C. 1997. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 94:1200-1205.
5. Chevaliez S, Rodriguez C, Pawlotsky JM. 2012. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 142:1303-1313.
6. Ghany MG, Strader DB, Thomas DL, Seeff LB. 2009. American association for the study of liver diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49:1335-1374.
7. Lange CM, Zeuzem S. 2011. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 55:692-701.
8. Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, Tillmann HL. 2009. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 46:210-215.
9. Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J. 2010. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol 48:18-21.
10. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, Takeda K. 2009. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 157:8-14.
11. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C. 2002. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: A model of viral-related steatosis. FASEB J 16:185-189.
12. Ross RS, Viazov S, Salloum S, Hilgard P, Gerken G, Roggendorf M. 2010. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 48:1161-1168.
13. Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, Lao XQ, Thompson A, Clark PJ, Gardner SD, McHutchison JG, McCarthy JJ. 2011. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 55:1195-1200.
14. Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H, Goto K, Peng LF, Chen WC, Chung RT. 2011. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 55:289-298.